Literature DB >> 26138827

Contralateral neck failure in lateralized oral squamous cell carcinoma.

Miriam Habib1, Jothi Murgasen1, Kan Gao2, Bruce Ashford1,3, Kerwin Shannon2, Ardalan Ebrahimi1,4,5, Jonathan R Clark1,2,5,6.   

Abstract

BACKGROUND: Elective treatment of the contralateral clinically node-negative (cN0) neck is not routinely recommended for lateralized oral cavity squamous cell carcinoma (SCC). We sought to determine the failure rate in the untreated contralateral neck in patients with lateralized oral SCC undergoing treatment of the primary and ipsilateral neck and to identify any features placing patients at sufficient risk of contralateral regional failure to justify elective treatment.
METHODS: We identified 688 patients with oral SCC undergoing curative surgery ± adjuvant therapy between 1985 and 2012 from a prospectively collected database. Patients with midline primaries and those undergoing bilateral neck treatment were excluded. The primary endpoint was isolated contralateral neck failure.
RESULTS: Of 481 patients, 14 (2.9%) developed isolated contralateral neck recurrence, with median time to recurrence of 8 months. Patients with poorly differentiated tumours or pathologically proven ipsilateral nodal metastases were at significantly higher risk of contralateral failure (hazard ratio (HR) 3.6, 95% confidence interval (CI) 1.1-11.9, P = 0.037 and HR 4.6, 95% CI 1.5-13.8, P = 0.006 respectively). Presence of both of these factors conferred a 10% risk of contralateral failure.
CONCLUSION: Patients with lateralized oral SCC undergoing treatment of the primary tumour and ipsilateral neck have a low rate of isolated contralateral neck failure. Although poorly differentiated primaries and ipsilateral nodal metastases were predictors of contralateral recurrence, the risk remains relatively modest in this subset of patients suggesting close observation may be more appropriate than elective treatment. Our results support current recommendations for observation of the cN0 contralateral neck in lateralized oral SCC.
© 2015 Royal Australasian College of Surgeons.

Entities:  

Keywords:  contralateral neck metastasis; lymph nodes; neck dissection; oral cancer

Mesh:

Year:  2015        PMID: 26138827     DOI: 10.1111/ans.13206

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  4 in total

1.  Guidelines for the Surgical Management of Oral Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Young-Hoon Joo; Jae-Keun Cho; Bon Seok Koo; Minsu Kwon; Seong Keun Kwon; Soon Young Kwon; Min-Su Kim; Jeong Kyu Kim; Heejin Kim; Innchul Nam; Jong-Lyel Roh; Young Min Park; Il-Seok Park; Jung Je Park; Sung-Chan Shin; Soon-Hyun Ahn; Seongjun Won; Chang Hwan Ryu; Tae Mi Yoon; Giljoon Lee; Doh Young Lee; Myung-Chul Lee; Joon Kyoo Lee; Jin Choon Lee; Jae-Yol Lim; Jae Won Chang; Jeon Yeob Jang; Man Ki Chung; Yuh-Seok Jung; Jae-Gu Cho; Yoon Seok Choi; Jeong-Seok Choi; Guk Haeng Lee; Phil-Sang Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-02-02       Impact factor: 3.372

2.  Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution.

Authors:  Aviram Mizrachi; Jocelyn C Migliacci; Pablo H Montero; Sean McBride; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2018-02-20       Impact factor: 5.337

3.  Contralateral Regional Recurrence in Lateralized or Paramedian Early-Stage Oral Cancer Undergoing Sentinel Lymph Node Biopsy-Comparison to a Historic Elective Neck Dissection Cohort.

Authors:  Rutger Mahieu; Inne J den Toom; Koos Boeve; Daphne Lobeek; Elisabeth Bloemena; Maarten L Donswijk; Bart de Keizer; W Martin C Klop; C René Leemans; Stefan M Willems; Robert P Takes; Max J H Witjes; Remco de Bree
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

4.  Treatment and Prognosis of Oral Cancer Patients with Confirmed Contralateral Neck Metastasis: A Multicenter Retrospective Analysis.

Authors:  Yuki Sakamoto; Mitsunobu Otsuru; Takumi Hasegawa; Masaya Akashi; Shin-Ichi Yamada; Hiroshi Kurita; Masaya Okura; Nobuhiro Yamakawa; Tadaaki Kirita; Souichi Yanamoto; Masahiro Umeda; Yuka Kojima
Journal:  Int J Environ Res Public Health       Date:  2022-07-28       Impact factor: 4.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.